This randomized controlled trial compared two different strategies of platelet inhibition in acute coronary syndrome with either clopidogrel or ticagrelor. This study may be of some relevance to nephrologists give the higher incidence of cardiovascular events in patient with renal insufficiency. While outcomes were better with ticagrelor, Nephrologists may be interested to know that renal function 12 months after the ACS had declined by 11% in the ticagrelor group vs 9% in those on clopidogrel (p<0.001). Individual practitioners will need to decide if this is clinically significant.
- The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients
- Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
- Performance of Temporary Hemodialysis Catheter Insertion by Nephrology Fellows and Attending Nephrologists